Group 1 - The core viewpoint of the article is that MicroTech Medical-B (02235.HK) expects significant revenue growth and a turnaround in net profit by the end of 2025, projecting revenue of at least RMB 650 million, which represents a year-on-year increase of approximately 88.1% [1] - The company anticipates a net profit attributable to the parent company of no less than RMB 38 million for the fiscal year 2025, a substantial improvement compared to a net loss of RMB 63.1 million in 2024, indicating a growth of RMB 101.1 million [1] - As of February 26, 2026, MicroTech Medical-B's stock closed at HKD 7.45, reflecting a 0.27% increase with a trading volume of 26,800 shares and a turnover of HKD 199,700 [1] Group 2 - The stock is primarily rated as "strong buy" by investment banks, with one bank issuing a strong buy rating in the last 90 days and a target average price of HKD 13.7 [1] - Huachuang Securities has recently provided a strong buy rating for MicroTech Medical-B, setting a target price of HKD 13.7 [1] - The market capitalization of MicroTech Medical-B is HKD 1.231 billion, ranking 18th in the medical device II industry [1]

Group 1 - The core point of the article is that MicroPort CardioFlow-B (02160.HK) has received a favorable review from the NMPA for its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN, which is expected to be the first domestically approved MRI-safe ICD with independent intellectual property rights [1] - The stock closed at HKD 0.79, up 2.6% with a trading volume of 8.472 million shares and a turnover of HKD 6.6143 million as of February 13, 2026 [1] - The stock has a market capitalization of HKD 4.902 billion and ranks 9th in the medical device II industry [1] Group 2 - MicroPort CardioFlow-B has a Return on Equity (ROE) of 0.24%, which is significantly higher than the industry average of -4.82%, ranking 17th out of 28 [2] - The company's operating revenue is HKD 368 million, compared to the industry average of HKD 1.201 billion, ranking 19th out of 28 [2] - The gross profit margin of MicroPort CardioFlow-B is 70.24%, which is above the industry average of 53.75%, ranking 6th out of 28 [2]

Group 1 - The core point of the article is that Peijia Medical-B (09996.HK) has submitted a CE mark registration application for its GeminiOne transcatheter edge-to-edge repair (TEER) system for treating mitral valve regurgitation, indicating steady progress in its global strategy [1] - The company has a market capitalization of HKD 4.288 billion and ranks 12th in the medical device II industry [1] - The stock has received a buy rating from one investment bank in the last 90 days, with CITIC Securities providing the latest buy rating for Peijia Medical-B [1] Group 2 - HighLife SAS is identified as the European partner for Peijia Medical-B in the CE mark registration process [1] - The article includes a summary of key indicators for Peijia Medical-B, although specific metrics are not detailed in the provided text [1]

Group 1 - The company, Aoxing Life Science Technology (06118.HK), expects to achieve a profit attributable to shareholders of not less than RMB 30 million for the year ending December 31, 2025, compared to an estimated profit of approximately RMB 16 million for the year ending December 31, 2024 [1][1][1] - As of February 6, 2026, Aoxing Life Science Technology's stock closed at HKD 0.8, down 4.76%, with a trading volume of 122,000 shares and a turnover of HKD 98,700 [1][1][1] - The company has a market capitalization of HKD 431 million and ranks 25th in the medical device II industry [1][1][1]

Core Viewpoint - The company, Qiming Medical-B (02500.HK), has filed a patent infringement lawsuit against Edwards Lifesciences Corp. and Edwards Lifesciences LLC through its wholly-owned subsidiary, Cardiovalve Ltd., in the U.S. District Court for Delaware [1] Company Summary - Qiming Medical-B has a market capitalization of HKD 1.491 billion and ranks 17th in the medical device II industry [1] - The company has a Return on Equity (ROE) of -26.56%, significantly lower than the industry average of -4.82% [1] - The company's operating revenue stands at HKD 427 million, compared to the industry average of HKD 1.201 billion, placing it 18th in the industry [1] - The net profit margin is -72.02%, while the industry average is -19.02%, ranking 26th [1] - The gross profit margin is 73.74%, which is higher than the industry average of 53.75%, ranking 2nd [1] - The company's debt ratio is 33.77%, compared to the industry average of 29.81%, ranking 21st [1] Industry Summary - There has been low attention from investment banks towards Qiming Medical-B, with no ratings given in the past 90 days [1]

Core Viewpoint - MicroTech Medical-B (02235.HK) announced the grant of a total of 3.3 million shares to 51 qualified individuals under its share incentive plan adopted on December 24, 2025, with the shares pending acceptance by the grantees [1] Company Summary - As of December 30, 2025, MicroTech Medical-B closed at HKD 7.93, up 2.72%, with a trading volume of 57,000 shares and a turnover of HKD 444,000 [1] - The stock has a market capitalization of HKD 1.282 billion, ranking 18th in the medical device II industry [1] Investment Ratings - The majority of investment banks have a buy rating for MicroTech Medical-B, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for MicroTech Medical-B [1] Key Financial Metrics - Return on Equity (ROE): -1.36%, compared to the industry average of -4.85%, ranking 19th [1] - Market capitalization: HKD 1.282 billion, with the industry average at HKD 5.097 billion, ranking 18th [1] - Revenue: HKD 441 million, with the industry average at HKD 1.2 billion, ranking 17th [1] - Net Profit Margin: -0.93%, compared to the industry average of -19.0%, ranking 17th [1] - Gross Margin: 51.66%, with the industry average at 54.03%, ranking 17th [1] - Debt Ratio: 10.8%, compared to the industry average of 29.53%, ranking 5th [1]

Core Viewpoint - Furuya Medical Technology (01696.HK) announced a leadership change, with current Executive Director and Chairman Liu Yi transitioning to a non-executive director role effective January 1, 2026, while retaining membership in the nomination committee [1] Company Summary - As of December 8, 2025, Furuya Medical Technology's stock closed at HKD 4.16, down 0.95%, with a trading volume of 570,800 shares and a turnover of HKD 2.39 million [1] - The company has a market capitalization of HKD 1.967 billion, ranking 14th in the medical device II industry [1] Investment Ratings - The majority of investment banks have a "Buy" rating for the stock, with one bank issuing a "Buy" rating in the last 90 days [1] - Huaxi Securities provided a recent report recommending a "Buy" rating for Furuya Medical Technology [1] Key Financial Metrics - Return on Equity (ROE): 4.44%, compared to the industry average of -4.03%, ranking 13th [1] - Market capitalization in Hong Kong: HKD 1.967 billion, with the industry average at HKD 5.116 billion, ranking 14th [1] - Revenue: HKD 346 million, while the industry average is HKD 1.195 billion, ranking 21st [1] - Net Profit Margin: 5.43%, compared to the industry average of -16.5%, ranking 16th [1] - Gross Profit Margin: 60.04%, above the industry average of 54.89%, ranking 13th [1] - Debt Ratio: 22.99%, lower than the industry average of 29.03%, ranking 13th [1]

Core Viewpoint - Peijia Medical-B (09996.HK) announced that its CEO and Chairman, Dr. Zhang Yi, will start purchasing company shares in the open market from December 1, 2025, with a total expenditure not exceeding HKD 15 million [1] Group 1: Company Actions - The CEO will begin share purchases on December 1, 2025 [1] - The total cost of the share buyback is expected to be no more than HKD 15 million [1] Group 2: Stock Performance - As of December 5, 2025, Peijia Medical-B closed at HKD 5.54, an increase of 0.73% [1] - The trading volume was 1.0137 million shares, with a total transaction value of HKD 5.6187 million [1] Group 3: Analyst Ratings - The stock has a predominant buy rating from investment banks, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Peijia Medical-B [1] Group 4: Market Position and Financial Metrics - Peijia Medical-B has a market capitalization of HKD 3.693 billion, ranking 11th in the medical device II industry [1] - Key financial metrics include: - ROE: -10.75% (industry average: -4.03%, ranking: 24th) [1] - Market capitalization: HKD 3.693 billion (industry average: HKD 5.177 billion, ranking: 11th) [1] - Revenue: HKD 668 million (industry average: HKD 1.195 billion, ranking: 15th) [1] - Net profit margin: -20.14% (industry average: -16.5%, ranking: 25th) [1] - Gross margin: 70.07% (industry average: 54.89%, ranking: 62nd) [1] - Debt ratio: 23.63% (industry average: 29.03%, ranking: 15th) [1]

Group 1 - The company, 加和国际控股 (08513.HK), announced a proposal to consolidate every 10 existing shares into 1 consolidated share [1] - Following the share consolidation, the trading unit on the Hong Kong Stock Exchange will change from 20,000 existing shares to 5,000 consolidated shares [1] - As of December 3, 2025, 加和国际控股's stock closed at HKD 0.12, reflecting a decrease of 3.97% with a trading volume of 280,000 shares and a transaction value of HKD 34,300 [1] Group 2 - 加和国际控股 has a market capitalization of HKD 103 million and ranks 28th in the medical device II industry [1] - There has been low attention from investment banks, with no ratings provided for the stock in the past 90 days [1]

Core Viewpoint - The chairman of MicroTech Medical (02235.HK), Zheng Pan, has reduced his stake by selling 2.09 million shares at a price of HKD 6.9 per share, totaling HKD 14.42 million, resulting in a new holding of approximately 38.70 million shares, representing 22.88% of the company [1][1][1]. Group 1: Shareholder Activity - Zheng Pan sold 2.09 million shares of MicroTech Medical at HKD 6.9 each, amounting to HKD 14.42 million [1][1][1]. - After the sale, his remaining shares are approximately 38.70 million, which is 22.88% of the total shares [1][1][1]. Group 2: Stock Performance - As of November 24, 2025, MicroTech Medical-B closed at HKD 6.8, unchanged from the previous trading day, with a trading volume of 79,500 shares and a turnover of HKD 532,700 [1][1][1]. - The stock has received a "Buy" rating from one investment bank in the last 90 days [1][1][1]. Group 3: Company Metrics - MicroTech Medical-B has a market capitalization of HKD 1.132 billion, ranking 21st in the medical device II industry [1][1][1]. - Key performance indicators include: - ROE: -1.36% (industry average: -4.03%, rank: 20) [1][1][1] - Market capitalization: HKD 1.132 billion (industry average: HKD 4.94 billion, rank: 21) [1][1][1] - Revenue: HKD 441 million (industry average: HKD 1.195 billion, rank: 18) [1][1][1] - Net profit margin: -0.93% (industry average: -16.5%, rank: 18) [1][1][1] - Gross profit margin: 51.66% (industry average: 54.89%, rank: 18) [1][1][1] - Debt ratio: 10.8% (industry average: 29.03%, rank: 5) [1][1][1].